Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

CNS Depressants: Alcohol and Nicotine01:27

CNS Depressants: Alcohol and Nicotine

215
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
215
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

305
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
305
Depressants01:28

Depressants

119
Depressant drugs, including alcohol and sedative-hypnotics, diminish central nervous system activity by enhancing the action of gamma-aminobutyric acid (GABA), a neurotransmitter that reduces brain activity and promotes relaxation. These substances can have various therapeutic uses but also pose significant risks, especially when misused or combined.
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
119
Analgesia and Pain Management01:25

Analgesia and Pain Management

632
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
632
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

255
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
255
Drug Dependence01:17

Drug Dependence

1.0K
Medications are typically administered to achieve therapeutic effects. Some drugs can modify an individual's mood and perception, frequently resulting in various enjoyable experiences. However, this can result in drug dependency, a condition marked by continuous drug use despite potential negative consequences. Drug dependency primarily falls into two categories: psychological and physical dependence. Psychological dependence occurs when the pleasurable feelings induced by the drug...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacists expand access to contingency management in patients with substance use disorders.

The mental health clinician·2026
Same author

Impact of psychiatric pharmacist-led ambulatory alcohol withdrawal management.

The mental health clinician·2025
Same author

Implementation and evaluation of interprofessional overdose review team recommendations following intentional or accidental overdose events.

The mental health clinician·2024
Same author

Addition of a clinical pharmacist practitioner to an inpatient addiction triage team and related medication outcomes.

The mental health clinician·2022
Same author

Pharmacist-led telemental health transitions of care clinic improves antidepressant medication continuity posthospitalization.

The mental health clinician·2020
Same author

Description of a pharmacist-led clinical video telehealth group clinic for opioid overdose prevention and naloxone education.

The mental health clinician·2019

Related Experiment Video

Updated: Jul 9, 2025

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.2K

Concurrent opioid and alcohol withdrawal management.

Michelle Colvard

    The Mental Health Clinician
    |December 7, 2023
    PubMed
    Summary

    Managing concurrent alcohol and opioid withdrawal is difficult due to limited evidence. This study explores safe medication strategies for simultaneous treatment of both conditions, offering clinical guidance.

    Keywords:
    alcohol withdrawalbenzodiazepinesmedications for alcohol use disordermedications for opioid use disorderopioid withdrawal

    More Related Videos

    Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
    05:12

    Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

    Published on: June 23, 2023

    912
    A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training
    07:50

    A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training

    Published on: January 29, 2017

    9.7K

    Related Experiment Videos

    Last Updated: Jul 9, 2025

    Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
    09:29

    Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

    Published on: August 4, 2022

    2.2K
    Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
    05:12

    Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

    Published on: June 23, 2023

    912
    A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training
    07:50

    A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training

    Published on: January 29, 2017

    9.7K

    Area of Science:

    • Clinical Medicine
    • Pharmacology
    • Addiction Medicine

    Background:

    • Concurrent alcohol and opioid withdrawal presents a complex clinical challenge.
    • Limited evidence exists for effective pharmacotherapy strategies for dual withdrawal.
    • Current practices often avoid combining first-line agents like benzodiazepines and opioid agonists.

    Purpose of the Study:

    • To demonstrate safe and effective pharmacotherapy strategies for managing concurrent alcohol and opioid withdrawal.
    • To provide clinical guidance for simultaneous medication treatment of dual withdrawal syndromes.
    • To optimize patient safety during the management of co-occurring withdrawal.

    Main Methods:

    • Case series approach detailing three patient scenarios.
    • Focus on simultaneous pharmacotherapy for alcohol and opioid withdrawal.
    • Emphasis on patient safety considerations.

    Main Results:

    • Successful simultaneous medication treatment was achieved in the presented cases.
    • Demonstrated feasibility of combining benzodiazepines and opioid agonists under specific protocols.
    • Highlighted the importance of individualized treatment plans.

    Conclusions:

    • Concurrent alcohol and opioid withdrawal can be managed effectively with tailored pharmacotherapy.
    • Careful consideration of patient safety and medication interactions is crucial.
    • Further research is warranted to establish evidence-based guidelines.